Palvella Raises $230M, Secures FDA Pre-NDA Meeting for QTORIN Q2
Palvella raised $230.0 million in an oversubscribed February equity offering and held $261.9 million cash as of March 31, 2026. The company secured an FDA pre-NDA meeting for QTORIN rapamycin in microcystic lymphatic malformations scheduled for Q2 2026, with NDA submission on track for H2 2026.
1. Financial Results and Balance Sheet
Palvella reported closing an oversubscribed public offering generating $230.0 million in gross proceeds in February and held $261.9 million in cash, cash equivalents and short-term investments as of March 31, 2026, bolstering its financial position to support late-stage development and commercialization activities.
2. Regulatory Milestones for QTORIN™ rapamycin
The company secured an FDA pre-New Drug Application meeting for its QTORIN™ rapamycin topical formulation in microcystic lymphatic malformations, scheduled for the second quarter of 2026, and reaffirmed its plan to submit an NDA in the second half of 2026; Palvella also strengthened global IP with a European patent covering topical compositions through 2038.
3. Pipeline Expansion and Upcoming Trials
Palvella plans to initiate a Phase 3 trial of QTORIN™ rapamycin for cutaneous venous malformations and a Phase 2 study of QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis in the second half of 2026, while a Phase 2 angiokeratomas study is underway with topline results expected in the second half of 2027, and additional platform candidates to be announced later in 2026.